Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume 32, Issue 9, Pages 1127-1136
Publisher
Elsevier BV
Online
2021-05-31
DOI
10.1016/j.annonc.2021.05.803
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score {greater than or equal to}10
- (2021) Zev A. Wainberg et al. CLINICAL CANCER RESEARCH
- The Impact of Molecular Subtype on Efficacy of Chemotherapy and Checkpoint Inhibition in Advanced Gastric Cancer
- (2020) Yohei Kubota et al. CLINICAL CANCER RESEARCH
- Association between Epstein-Barr virus infection and gastric cancer: a systematic review and meta-analysis
- (2020) Ahmad Tavakoli et al. BMC CANCER
- Tumor mutational burden (TMB) standardization initiatives: Recommendations for consistent TMB assessment in clinical samples to guide immunotherapy treatment decisions
- (2019) Albrecht Stenzinger et al. GENES CHROMOSOMES & CANCER
- Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer
- (2019) Saori Mishima et al. Journal for ImmunoTherapy of Cancer
- Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432
- (2019) F Wang et al. ANNALS OF ONCOLOGY
- LBA80Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407
- (2019) L Paz-Ares et al. ANNALS OF ONCOLOGY
- Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas
- (2018) Yang Liu et al. CANCER CELL
- Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
- (2018) Kohei Shitara et al. LANCET
- Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer
- (2018) Seung Tae Kim et al. NATURE MEDICINE
- Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer
- (2018) Charles S. Fuchs et al. JAMA Oncology
- Association of high tissue TMB and atezolizumab efficacy across multiple tumor types.
- (2018) Fatema A. Legrand et al. JOURNAL OF CLINICAL ONCOLOGY
- Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
- (2018) Razvan Cristescu et al. SCIENCE
- Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
- (2017) Aaron M. Goodman et al. MOLECULAR CANCER THERAPEUTICS
- Clinical application of a cancer genomic profiling assay to guide precision medicine decisions
- (2017) Cheryl Eifert et al. Personalized Medicine
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
- (2017) Zachary R. Chalmers et al. Genome Medicine
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes
- (2015) Razvan Cristescu et al. NATURE MEDICINE
- Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
- (2015) E. M. Van Allen et al. SCIENCE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice
- (2015) Luís Felipe Campesato et al. Oncotarget
- Comprehensive molecular characterization of gastric adenocarcinoma
- (2014) Adam J. Bass et al. NATURE
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
- (2010) A. McKenna et al. GENOME RESEARCH
- Fast and accurate short read alignment with Burrows-Wheeler transform
- (2009) H. Li et al. BIOINFORMATICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation